Get all premium features to the best stock analysis tool

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Amphastar Pharmaceuticals (AMPH) is rated a Buy, with ~81% upside to a $33 fair value, despite margin pressures for 2026. AMPH faces declining sales in legacy products but expects mid- to high-single-digit revenue growth in 2026, led by Baqsimi and new launches. I estimate operating margin to dip to 22% in 2026 due to increased expenses, recovering to 26% by 2030 as higher-margin pipeline products ramp up.

RANCHO CUCAMONGA, CA / ACCESS Newswire / March 4, 2026 / announced today that Bill Peters, CFO, and Dan Dischner, SVP of Corp. Communication, will be presenting at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 1:30 pm ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.

Amphastar Pharmaceuticals remains a 'Hold' as growth and margin headwinds persist amid its transition from generics to a proprietary pipeline. AMPH's legacy generics are declining, branded products face growth deceleration, and margins are pressured by product mix and rising R&D/SG&A costs. FY26 revenue guidance was cut to mid- to high-single-digit growth; AMP-007's contribution is uncertain, and preclinical pipeline catalysts are years away.

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.92 per share a year ago.